PTH and osteosarcoma: In addition to PTHrP, a potential carcinogenic effect of PTH itself presented when the phase 3 trials for teriparatide (PTH1-34) were prematurely terminated because Fischer rats in the preclinical setting had developed osteosarcoma in a dose-dependent manner when treated with supratherapeutic doses of teriparatide (23).